Epizyme (NASDAQ:EPZM) had its price target hoisted by Morgan Stanley from $26.00 to $28.00 in a research note issued to investors on Friday, BenzingaRatingsTable reports. Morgan Stanley currently has an overweight rating on the biopharmaceutical company’s stock.
A number of other analysts have also recently weighed in on the stock. BidaskClub raised shares of Epizyme from a hold rating to a buy rating in a report on Tuesday, December 31st. Leerink Swann lowered shares of Epizyme from an outperform rating to a market perform rating and set a $18.00 price target for the company. in a report on Friday. Wedbush boosted their price objective on shares of Epizyme from $24.00 to $30.00 and gave the company an outperform rating in a research report on Friday. ValuEngine lowered shares of Epizyme from a hold rating to a sell rating in a research note on Thursday, November 7th. Finally, Svb Leerink lowered shares of Epizyme from an outperform rating to a market perform rating in a research note on Friday. Two analysts have rated the stock with a sell rating, two have issued a hold rating and eight have assigned a buy rating to the company. The company has a consensus rating of Buy and a consensus price target of $25.13.
Shares of NASDAQ EPZM opened at $21.36 on Friday. The company has a current ratio of 10.90, a quick ratio of 10.90 and a debt-to-equity ratio of 0.03. The company has a market capitalization of $1.95 billion, a price-to-earnings ratio of -13.27 and a beta of 2.68. Epizyme has a twelve month low of $8.98 and a twelve month high of $27.82. The business has a 50 day simple moving average of $22.62 and a 200-day simple moving average of $15.29.
In other Epizyme news, CEO Robert B. Bazemore sold 3,002 shares of the stock in a transaction on Friday, January 24th. The stock was sold at an average price of $24.62, for a total value of $73,909.24. Following the sale, the chief executive officer now directly owns 93,744 shares of the company’s stock, valued at $2,307,977.28. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Shefali Agarwal sold 1,843 shares of the stock in a transaction on Friday, January 24th. The stock was sold at an average price of $24.64, for a total value of $45,411.52. Following the completion of the sale, the insider now directly owns 63,276 shares in the company, valued at $1,559,120.64. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 13,549 shares of company stock valued at $297,231. 16.60% of the stock is owned by company insiders.
Hedge funds and other institutional investors have recently modified their holdings of the business. Vigilant Capital Management LLC acquired a new stake in Epizyme in the fourth quarter worth $32,000. Zurcher Kantonalbank Zurich Cantonalbank increased its position in Epizyme by 29.3% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,564 shares of the biopharmaceutical company’s stock worth $57,000 after buying an additional 1,262 shares during the period. Perigon Wealth Management LLC acquired a new stake in Epizyme in the fourth quarter worth $201,000. United Services Automobile Association acquired a new stake in Epizyme in the second quarter worth $134,000. Finally, Man Group plc acquired a new stake in Epizyme in the second quarter worth $222,000. 87.04% of the stock is currently owned by hedge funds and other institutional investors.
Epizyme, Inc, a late-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases primarily in the United States. The company's lead products candidate is tazemetostat, an inhibitor of the EZH2 histone methyltransferase, which is in the Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function; and Phase II clinical trial for adults and Phase I clinical trial for children with epithelioid sarcoma and other INI1-negative solid tumors.
Recommended Story: Holder of Record
Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.